Nouscom raises $72m in Series C financing round to develop cancer vaccines

Swiss biotech Nouscom has raised €67.5m ($72m) in a Series C funding round co-led by Andera Partners, Bpifrance and M Ventures.

Revelation Partners, Indaco Venture Partners, Panakès Partners, X-Gen Ventures, 5AM Ventures, EQT Life Sciences, Versant Ventures and other undisclosed investors took part in the financing round.